Pfizer dips into translational regulation for cancer with eFFECTOR deal

Pfizer’s deal with eFFECTOR points to translational regulators as an emerging target source

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex subunit eIF4E to treat cancer.

eFFECTOR Therapeutics Inc. will receive $15 million up front and up to

Read the full 521 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE